Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Long-Term Deferred Tax (2023 - 2025)

Telix Pharmaceuticals has reported Long-Term Deferred Tax over the past 3 years, most recently at $59.4 million for Q4 2025.

  • Quarterly Long-Term Deferred Tax rose 94.19% to $59.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $59.4 million through Dec 2025, up 94.19% year-over-year, with the annual reading at $59.4 million for FY2025, 105.23% up from the prior year.
  • Long-Term Deferred Tax was $59.4 million for Q4 2025 at Telix Pharmaceuticals, up from $30.6 million in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $59.4 million in Q4 2025 and troughed at $13.3 million in Q4 2023.
  • The 3-year median for Long-Term Deferred Tax is $30.6 million (2024), against an average of $34.4 million.
  • Year-over-year, Long-Term Deferred Tax surged 129.56% in 2024 and then surged 94.19% in 2025.
  • A 3-year view of Long-Term Deferred Tax shows it stood at $13.3 million in 2023, then surged by 129.56% to $30.6 million in 2024, then soared by 94.19% to $59.4 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Long-Term Deferred Tax are $59.4 million (Q4 2025), $30.6 million (Q4 2024), and $13.3 million (Q4 2023).